Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration.

Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ.

Nat Struct Biol. 2003 Jul;10(7):541-4.

PMID:
12808446
2.

Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.

Schroeck F, Arroyo de Prada N, Sperl S, Schmitt M, Viktor M.

Biol Chem. 2002 Jul-Aug;383(7-8):1143-9. Review.

PMID:
12437099
3.

Matrix metalloproteinases and cellular fibrinolytic activity.

Lijnen HR.

Biochemistry (Mosc). 2002 Jan;67(1):92-8. Review.

4.

Vitronectin.

Schvartz I, Seger D, Shaltiel S.

Int J Biochem Cell Biol. 1999 May;31(5):539-44. Review.

PMID:
10399314
5.

Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling.

Stefansson S, McMahon GA, Petitclerc E, Lawrence DA.

Curr Pharm Des. 2003;9(19):1545-64. Review.

PMID:
12871067
7.

Recombinant plasminogen activator inhibitor type 1: a review of structural, functional, and biological aspects.

Reilly TM, Mousa SA, Seetharam R, Racanelli AL.

Blood Coagul Fibrinolysis. 1994 Feb;5(1):73-81. Review.

PMID:
8180342
8.

The PAI-1/vitronectin interaction: two cats in a bag?

Deng G, Royle G, Seiffert D, Loskutoff DJ.

Thromb Haemost. 1995 Jul;74(1):66-70. Review. No abstract available.

PMID:
8578527
9.

Pleiotropic functions of plasminogen activator inhibitor-1.

Lijnen HR.

J Thromb Haemost. 2005 Jan;3(1):35-45. Review.

10.

Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.

Reuning U, Magdolen V, Hapke S, Schmitt M.

Biol Chem. 2003 Aug;384(8):1119-31. Review.

PMID:
12974381
11.

Plasminogen activator inhibitor-1.

Gils A, Declerck PJ.

Curr Med Chem. 2004 Sep;11(17):2323-34. Review.

PMID:
15379715
12.

The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo.

Van De Craen B, Declerck PJ, Gils A.

Thromb Res. 2012 Oct;130(4):576-85. doi: 10.1016/j.thromres.2012.06.023. Epub 2012 Jul 15. Review.

PMID:
22801256
13.

Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis.

Durand MK, Bødker JS, Christensen A, Dupont DM, Hansen M, Jensen JK, Kjelgaard S, Mathiasen L, Pedersen KE, Skeldal S, Wind T, Andreasen PA.

Thromb Haemost. 2004 Mar;91(3):438-49. Review.

PMID:
14983218
14.

Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis (Review).

Chorostowska-Wynimko J, Skrzypczak-Jankun E, Jankun J.

Int J Mol Med. 2004 Jun;13(6):759-66. Review.

PMID:
15138609
15.

Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent.

Cale JM, Lawrence DA.

Curr Drug Targets. 2007 Sep;8(9):971-81. Review.

PMID:
17896949
16.

Plasminogen activator inhibitor-1 in vascular thrombosis.

Westrick RJ, Eitzman DT.

Curr Drug Targets. 2007 Sep;8(9):966-1002. Review.

PMID:
17896948
17.

Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment.

Czekay RP, Loskutoff DJ.

Exp Biol Med (Maywood). 2004 Dec;229(11):1090-6. Review.

PMID:
15564434
18.

PAI-1 - a potential therapeutic target in cancer.

Andreasen PA.

Curr Drug Targets. 2007 Sep;8(9):1030-41. Review.

PMID:
17896954
19.

[The role of PAI-1 in thrombotic events].

Orbe J, Montes R, Páramo JA.

Med Clin (Barc). 1999 Jun 19;113(2):63-9. Review. Spanish. No abstract available.

PMID:
10425624
20.

Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease.

Dellas C, Loskutoff DJ.

Thromb Haemost. 2005 Apr;93(4):631-40. Review.

PMID:
15841306

Supplemental Content

Support Center